Vascular Endothelial Growth Factor Receptor Articles & Analysis
4 news found
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors AVEO Oncology (Nasdaq: AVEO), a commercial stage, ...
NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply ...
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. “I am proud of the entire AVEO team this year, as we accomplished several key milestones in the face of what remains a challenging environment with the ongoing COVID-19 pandemic,” said Michael Bailey, President and Chief Executive ...
-SITC 2021, re-hosted face to face meeting for the first time in 2 years due to COVID-19…topic for overcoming tolerance of Immuno-oncology -International researchers pay attention to immuno-oncology GI-101’s material excellence that had the mechanism of overcoming tolerance GI Innovation revealed KEYNOTE-B59’s clinical research process of GI-101(CD80/IL-2 variant bispecific ...